Nomura Asset Management International’s Ligand Pharmaceuticals LGND Stock Holding History

Nomura Asset Management International’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$180M	Sell	568,371 -4,941	-0.9%	-$1.16M	0.27%	55
2026 Q1	$114M	Sell	573,312 -70,781	-11%	-$14M	0.2%	108
2025 Q4	$122M	Buy	+644,093	New	+$124M	0.18%	128

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nomura Asset Management International's LGND Position: Q2 2026 in Review

Nomura Asset Management International reduced its Ligand Pharmaceuticals (LGND) stake by 0.86% in Q2 2026, selling an estimated $1.16M and leaving 568,371 shares worth $180M. The position accounts for 0.27% of the portfolio, ranked #55.

Nomura Asset Management International first reported a position in LGND in Q4 2025 and has held it in 3 quarters since. 413 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Nomura Asset Management International held 568,371 shares of Ligand Pharmaceuticals worth $180M as of Q2 2026.
Nomura Asset Management International sold 4,941 Ligand Pharmaceuticals shares in Q2 2026, an estimated $1.16M.
Ligand Pharmaceuticals made up 0.27% of Nomura Asset Management International's portfolio in Q2 2026, its #55 holding.
Nomura Asset Management International first reported a position in Ligand Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
413 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Nomura Asset Management International's 13F filing for Q2 2026, filed 14 Aug 2026.